scholarly journals Reduction of severe intraventricular hemorrhage, a tertiary single-center experience: incidence trends, associated risk factors, and hospital policy

2020 ◽  
Vol 36 (12) ◽  
pp. 2971-2979
Author(s):  
Wafa Sattam M. Alotaibi ◽  
Nada S. Alsaif ◽  
Ibrahim A. Ahmed ◽  
Aly Farouk Mahmoud ◽  
Kamal Ali ◽  
...  
Keyword(s):  
Risk Factors ◽  
Clinical Practice ◽  
Intraventricular Hemorrhage ◽  
Retrospective Chart Review ◽  
Multivariate Logistic Regression Model ◽  
Hospital Policy ◽  
Incidence Trends ◽  
Single Center Experience ◽  
The Impact ◽  
Neonatal Risk Factors

Abstract Objectives To determine the incidence, trends, maternal and neonatal risk factors of severe intraventricular hemorrhage (IVH) among infants born 24–32 weeks and/or < 1500 g, and to evaluate the impact of changing of hospital policies and unit clinical practice on the IVH incidence. Study design Retrospective chart review of preterm infants with a gestational age (GA) of 24–326 weeks and/or weight of < 1500 g born at King Abdulaziz Medical City–Riyadh (KAMC-R), Saudi Arabia, from 2016 to 2018. Multivariate logistic regression model was constructed to determine the probability of developing severe IVH and identify associations with maternal and neonatal risk factors. Results Among 640 infants, the overall incidence of severe IVH was 6.4% (41 infants), and its rate decreased significantly, from 9.4% in 2016 to 4.5% and 5% in 2017 and 2018 (p = 0.044). Multivariate analysis revealed that caesarian section delivery decreased the risk of severe IVH in GA group 24–27 weeks (p = 0.045). Furthermore use of inotropes (p = 0.0004) and surfactant (p = 0.0003) increased the risk of severe IVH. Despite increasing use of inotropes (p = 0.024), surfactant therapy (p = 0.034), and need for delivery room intubation (p = 0.015), there was a significant reduction in the incidence of severe IVH following the change in unit clinical practice and hospital policy (p = 0.007). Conclusion Cesarean section was associated with decreased all grades of IVH and severe IVH, while use of inotropes was associated with increased severe IVH. The changes in hospital and unit policy were correlated with decreased IVH during the study period.

Febrile Neutropenia in Lymphoma Patients Is Associated with Substantial Resource Use and Healthcare Costs in Clinical Practice in Spain.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 5512-5512 ◽  
Author(s):  
A. López ◽  
J.D. Alonso ◽  
J. Gómez-Codina ◽  
A. Novo ◽  
C. Herrera ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Febrile Neutropenia ◽  
Resource Use ◽  
Healthcare Costs ◽  
Length Of Hospital Stay ◽  
Retrospective Chart Review ◽  
Substantial Impact ◽  
Ct Dose ◽  
Common Clinical Practice ◽  
The Impact

Abstract Background Despite the significant impact of chemotherapy-induced febrile neutropenia (FN) on patients (pts) with cancer and its consequences for health care costs, there have been no studies in common clinical practice in Spain assessing the burden and economic impact of this complication. Methods This is a sub-analysis of lymphoma pts included in a multicentre, retrospective, chart review of adult pts from 16 Spanish hospitals who suffered from at least one FN episode related to cytotoxic chemotherapy (CT). Resource use and subsequent costs including days of hospitalization, number of transfusions, number and type of complementary tests, use of colony-stimulating factors (CSFs), and use of antibiotics and other drugs to manage FN were assessed for each episode. The impact of FN on planned CT was also analysed in terms of dose delays (DD) and/or reductions (DR). Results Medical charts from 194 pts were reviewed, 67 (34.5%) of whom had lymphoma, which accounted for 87 documented FN episodes included in this analysis. The median (range) age of patients was 62 (19–85) years, 31.7% had aggressive NHL, and 58.2% were treated with CHOP-like CT. FN appeared during first CT cycle in 61.2% of the pts. Hospitalization was required in 100% of the pts and the median length of hospital stay due to FN was 8 days (p25:6–p75:11). During an FN episode, 42% of pts required ≥1 transfusion, 100% needed a blood test and 98.9% a blood culture. Microbiologically documented infection appeared in 33% of FN episodes. All pts were treated with antibiotics (69.3% with cephalosporins) and CSFs were used in 64.8% of pts. In 40.9% of episodes, FN impacted on planned CT dose and/or schedule: DR was observed in 16.7% of pts, DD in 24.0% and CT withdrawal in 15.2%. Conclusions FN has a substantial impact on resource use and associated costs in pts with lymphoma. Hospitalization and antibiotic treatment were the main drivers of the cost associated with the management of FN in current clinical practice. Furthermore, FN has a meaningful effect on planned CT dose and/or schedule, with potential consequences for treatment outcome. Mean (SD) healthcare costs per FN episode (All cost data expressed as €) Hospitalization Transfusions Complementary Tests CSFs Antibiotics and Other Drugs Total 3,557.17 (3,050.44) 43.24 (58.59) 162.77 (135.36) 223.39(231.40) 527.67 (448.56) 4,514.24 (3,392.20)

Warfarin-Induced Rapid Rise in INR Post–Cardiac Surgery Is Not Associated With Increased Bleeding Risk

2019 ◽  
Vol 53 (12) ◽  
pp. 1184-1191 ◽  
Author(s):  
Logan M. Olson ◽  
Andrea M. Nei ◽  
Ross A. Dierkhising ◽  
David L. Joyce ◽  
Scott D. Nei
Keyword(s):  
Risk Factors ◽  
Cardiac Surgery ◽  
Warfarin Dose ◽  
Retrospective Chart Review ◽  
Female Gender ◽  
Bleeding Risk ◽  
Hospital Length Of Stay ◽  
Rapid Rise ◽  
The Impact ◽  
Post Cardiac Surgery

Background: Post–cardiac surgery bleeding can have devastating consequences, and it is unknown if warfarin-induced rapid international normalized ratio (INR) rise during the immediate postoperative period increases bleed risk. Objective: To determine the impact of warfarin-induced rapid-rise INR on post–cardiac surgery bleeding. Methods: This was a single-center, retrospective chart review of post–cardiac surgery patients initiated on warfarin at Mayo Clinic Hospital, Rochester. Patients were grouped based on occurrence or absence of rapid-rise INR (increase ≥1.0 within 24 hours). The primary outcome compared bleed events between groups. Secondary outcomes assessed hospital length of stay (LOS) and identified risk factors associated with bleed events and rapid rise in INR. Results: During the study period, 2342 patients were included, and 56 bleed events were evaluated. Bleed events were similar between rapid-rise (n = 752) and non–rapid-rise (n = 1590) groups in both univariate (hazard ratio [HR] = 1.22; P = 0.594) and multivariable models (HR = 1.24; P = 0.561). Those with rapid-rise INR had longer LOS after warfarin administration (discharge HR = 0.84; P = 0.0002). The most common warfarin dose immediately prior to rapid rise was 5 mg. Risk factors for rapid-rise INR were low body mass index, female gender, and cross-clamp time. Conclusion and Relevance: This represents the first report to assess warfarin-related rapid-rise INR in post–cardiac surgery patients and found correlation to hospital LOS but not bleed events. Conservative warfarin dosing may be warranted until further research can be conducted.

A prediction model for chemotherapy-associated thrombocytopenia in cancer patients

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 8616-8616 ◽  
Author(s):  
N. M. Kuderer ◽  
C. W. Francis ◽  
J. Crawford ◽  
D. C. Dale ◽  
D. A. Wolff ◽  
...  
Keyword(s):  
Risk Factors ◽  
Prediction Model ◽  
Likelihood Ratio ◽  
Test Performance ◽  
Dose Intensity ◽  
High Specificity ◽  
Performance Characteristics ◽  
Multivariate Logistic Regression Model ◽  
Model Based ◽  
The Impact

8616 Background: Thrombocytopenia (TP) can lead to serious complications, however, little is known about the incidence and risk factors for chemotherapy-associated TP. A prospective, nationwide cohort study was undertaken to better define the impact of TP in cancer treatment. Methods: 2,842 patients with cancer of the breast, lung, colon, ovary or lymphoma initiating a new chemotherapy regimen have been prospectively enrolled at 115 randomly selected US community oncology practices between 2002 and 2005. Risk factors for chemotherapy-associated TP were identified, a multivariate logistic regression model based on pretreatment characteristics was developed, and test performance characteristics were estimated. Results: Over a median of 3 cycles of chemotherapy, minimum recorded platelet counts were: ≥150K in 53% of patients; 100–150K in 26%; 75–100K in 8%; 50–75K in 6% and <50K in 7%. Significant independent predictive factors for platelets <75K include type of cancer (P<.0001), type of chemotherapy including gemcitabine-based (P<.0001), anthracycline-based (P<.0001) and platinum-based (P<.0001) regimens, prior chemotherapy (P<.0001) or surgery (P=.005), age (P=.015), Caucasian ethnicity (P=.022), body surface area (P=.0001), planned relative dose intensity ≥85% (P=.082), diabetes (P=.018), pulmonary disease (P=.011), abnormal baseline platelets (P<.0001), hematocrit (P=0.030), alkaline phosphatase (P=.072) or albumin (P=.017). Model fit was good (Chi-square, P<.0001), R2 = 0.735 and c-statistic = 0.816 [95% CI: 0.792–0.840, P<.0001]. Model test performance characteristics [95% CI] at a ≥20% risk of TP include: sensitivity 56% [51–61]; specificity 88% [87–89]; likelihood ratio positive 4.63 [4.02–5.33]; likelihood ratio negative 0.50 [0.45–0.57]; and diagnostic odds ratio 9.22 [7.23–11.75]. Validation of the model is underway. Conclusions: This prediction model based on pretreatment factors identifies with high specificity patients at risk for clinically important chemotherapy-associated thrombocytopenia early in the treatment course. It may provide a valuable tool for guiding chemotherapy and new supportive care measures. [Table: see text]

Establishment of Prediction Models for venous thromboembolism in non-oncological urological inpatients--a single center experience

2020 ◽  
Author(s):  
Kaixuan Li ◽  
Haozhen Li ◽  
Quan Zhu ◽  
Ziqiang Wu ◽  
Zhao Wang ◽  
...  
Keyword(s):  
Risk Factors ◽  
Logistic Regression ◽  
Venous Thromboembolism ◽  
Prediction Model ◽  
Regression Model ◽  
Logistic Regression Model ◽  
Prediction Models ◽  
Predictive Ability ◽  
Multivariate Logistic Regression Model ◽  
Single Center Experience

Abstract Background To establish prediction models for venous thromboembolism (VTE) in non-oncological urological inpatients. Methods A retrospective analysis of 1453 inpatients was carried out and the risk factors for VTE had been clarified our previous studies. Results Risk factors included the following 5 factors: presence of previous VTE (X1), presence of anticoagulants or anti-platelet agents treatment before admission (X2), D-dimer value (≥ 0.89 µg/ml, X3), presence of lower extremity swelling (X4), presence of chest symptoms (X5). The logistic regression model is Logit (P) = − 5.970 + 2.882 * X1 + 2.588 * X2 + 3.141 * X3 + 1.794 * X4 + 3.553 * X5. When widened the p value to not exceeding 0.1 in multivariate logistic regression model, two addition risk factors were enrolled: Caprini score (≥ 5, X6), presence of complications (X7). The prediction model turns into Logit (P) = − 6.433 + 2.696 * X1 + 2.507 * X2 + 2.817 * X3 + 1.597 * X4 + 3.524 * X5 + 0.886 * X6 + 0.963 * X7. Internal verification results suggest both two models have a good predictive ability, but the prediction accuracy turns to be both only 43.0% when taking the additional 291 inpatients’ data in the two models. Conclusion We built two similar novel prediction models to predict VTE in non-oncological urological inpatients. Trial registration: This trial was retrospectively registered at http://www.chictr.org.cn/index.aspx under the public title“The incidence, risk factors and establishment of prediction model for VTE n urological inpatients” with a code ChiCTR1900027180 on November 3, 2019. (Specific URL to the registration web page: http://www.chictr.org.cn/showproj.aspx?proj=44677).

The Impact of Transitions of Care Pharmacist Services and Identification of Risk Predictors in Heart Failure Readmission

2019 ◽  
pp. 089719001988417 ◽  
Author(s):  
Marci Wood ◽  
Tracey Sweeney ◽  
Molly Trayah ◽  
Maria Civalier ◽  
Wesley McMillian
Keyword(s):  
Risk Factors ◽  
Heart Failure ◽  
Angiotensin Receptor Blockers ◽  
Significant Risk ◽  
Retrospective Chart Review ◽  
Transitions Of Care ◽  
Converting Enzyme Inhibitors ◽  
Increased Risk ◽  
Risk Predictors ◽  
The Impact

Background: Heart failure (HF) is a prevalent and costly disease state for adult Americans, with 30-day readmissions rates for patients with HF utilized to limit hospital compensation. Objective: To determine the impact of the transitions of care (TOC) service at our institution on 30-day all-cause and HF readmissions and identify predictive risk factors for 30-day all-cause readmission. Methods: Retrospective chart review of patients aged 18 years and older admitted with HF and all subsequent readmissions between October 1, 2015, and September 30, 2017. A weighted logistic regression model was developed to determine risk factors for 30-day all-cause readmission. Results: There were no significant differences in all-cause or HF readmission rates analyzed by TOC service involvement. Significant risk predictors for 30-day all-cause readmission included discharge to a rehabilitation facility (odds ratio [OR] = 9.3) or home with home health (OR = 1.6) versus home with self-care. Comorbidities associated with an increased risk of 30-day all-cause readmission included diabetes, coronary artery disease, and aortic stenosis. Use of angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and spironolactone was associated with decreased risk of 30-day all-cause readmission. Conclusion: Identified predictors in the patient population with HF at our institution may be used to target patients at increased risk of all-cause readmission within 30 days.

scholarly journals Risk Factors for Short- and Long-Term Outcomes in Children With STEC-HUS/D+ HUS: A Single-Center Experience

2018 ◽  
Vol 5 ◽  
pp. 2333794X1881692 ◽  
Author(s):  
Judith Sebestyen VanSickle ◽  
Tarak Srivastava ◽  
Uri S. Alon
Keyword(s):  
Risk Factors ◽  
Urine Output ◽  
Kidney Injury ◽  
Retrospective Chart Review ◽  
Female Gender ◽  
Neurological Complications ◽  
Long Term Outcomes ◽  
Single Center Experience ◽  
Uremic Syndrome

Background. Hemolytic uremic syndrome (HUS) is one of the common causes for acute kidney injury in childhood. Objective. The goals of our study were to identify risk factors for short-term complications and long-term outcomes of chronic kidney disease (CKD) in Shiga toxin–producing Escherichia coli (STEC)-HUS and other diarrhea positive (D+) HUS. Methods. Retrospective chart review was obtained of 58 pediatric patients treated for STEC-HUS and other D+ HUS between February 2002 and January 2011. Results. Thirty-three patients (56.9%) required dialysis. Dialysis was more likely initiated if a patient was a female ( P < .012), oliguric (urine output < 0.5 mL/kg/h, P < .0005), or hemoglobin (HGB) level >10 g/dL ( P = .009) at admission. Neurological complications developed only among 5 dialyzed patients ( P < .042), and were more common if the patient received hemodialysis (HD) compared with peritoneal dialysis ( P < .0005). CKD was noted during the subsequent follow-up clinic visits in 5 patients (8.6%). Those who developed CKD received HD ( P = .002), dialysis for >10 days ( P = .0004), or HGB level >10 g/dL ( P = .034) at admission. Conclusions. Children with STEC-HUS/D+ HUS who may need dialysis are identified by female gender, lower urine output, higher serum creatinine level, and higher HGB at admission. They are at higher risk developing central nervous system complications especially if they needed HD. Children requiring >10 days of dialysis are at risk for development of CKD.

scholarly journals Lung function trajectories in children with post-prematurity respiratory disease: identifying risk factors for abnormal growth

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Jonathan C. Levin ◽  
Catherine A. Sheils ◽  
Jonathan M. Gaffin ◽  
Craig P. Hersh ◽  
Lawrence M. Rhein ◽  
...  
Keyword(s):  
Risk Factors ◽  
Mechanical Ventilation ◽  
Lung Function ◽  
Respiratory Disease ◽  
Maternal Risk ◽  
Abnormal Growth ◽  
Observational Cohort ◽  
Multivariable Analyses ◽  
The Impact ◽  
Neonatal Risk Factors

Abstract Background Survivors of prematurity are at risk for abnormal childhood lung function. Few studies have addressed trajectories of lung function and risk factors for abnormal growth in childhood. This study aims to describe changes in lung function in a contemporary cohort of children born preterm followed longitudinally in pulmonary clinic for post-prematurity respiratory disease and to assess maternal and neonatal risk factors associated with decreased lung function trajectories. Methods Observational cohort of 164 children born preterm ≤ 32 weeks gestation followed in pulmonary clinic at Boston Children’s Hospital with pulmonary function testing. We collected demographics and neonatal history. We used multivariable linear regression to identify the impact of neonatal and maternal risk factors on lung function trajectories in childhood. Results We identified 264 studies from 82 subjects with acceptable longitudinal FEV1 data and 138 studies from 47 subjects with acceptable longitudinal FVC and FEV1/FVC data. FEV1% predicted and FEV1/FVC were reduced compared to childhood norms. Growth in FVC outpaced FEV1, resulting in an FEV1/FVC that declined over time. In multivariable analyses, longer duration of mechanical ventilation was associated with a lower rate of rise in FEV1% predicted and greater decline in FEV1/FVC, and postnatal steroid exposure in the NICU was associated with a lower rate of rise in FEV1 and FVC % predicted. Maternal atopy and asthma were associated with a lower rate of rise in FEV1% predicted. Conclusions Children with post-prematurity respiratory disease demonstrate worsening obstruction in lung function throughout childhood. Neonatal risk factors including exposure to mechanical ventilation and postnatal steroids, as well as maternal atopy and asthma, were associated with diminished rate of rise in lung function. These results may have implications for lung function trajectories into adulthood.

Acute Kidney Injury Defined by Fluid Corrected Creatinine in Neonates After the Norwood Procedure

2018 ◽  
Vol 9 (5) ◽  
pp. 513-521 ◽  
Author(s):  
Megan McFerson SooHoo ◽  
Sonali S. Patel ◽  
James Jaggers ◽  
Sarah Faubel ◽  
Katja M. Gist
Keyword(s):  
Risk Factors ◽  
Acute Kidney Injury ◽  
Serum Creatinine ◽  
Kidney Injury ◽  
Retrospective Chart Review ◽  
Adverse Outcomes ◽  
Norwood Procedure ◽  
Multivariable Logistic Regression Analysis ◽  
Increased Risk ◽  
The Impact

Background: Both the Norwood procedure and acute kidney injury (AKI) are associated with significant morbidity and mortality. The impact of AKI by measured and fluid corrected serum creatinine on outcomes after the Norwood procedure has not been previously studied. The purpose of this study was to (1) identify the incidence of AKI, (2) determine AKI risk factors, and (3) evaluate outcomes in patients with AKI using both measured and fluid corrected serum creatinine. Methods: Single-center retrospective chart review from 2009 to 2015 including neonates who underwent the Norwood procedure. Acute kidney injury was defined by the Kidney Disease Improving Global Outcomes staging criteria using both measured and fluid corrected serum creatinine. Multivariable logistic regression analysis was performed to determine the risk factors associated with AKI. Results: Ninety-five neonates underwent the Norwood procedure. Correcting for fluid overload increased the incidence of AKI from 40% to 44%, increased AKI severity in 15 patients, and improved the identification of adverse outcomes associated with AKI. Patients palliated with the modified Blalock-Taussig shunt (mBTS) had a 9.4 greater odds of fluid corrected AKI compared to those palliated with a right ventricle to pulmonary artery conduit (95% confidence interval [95% CI]: 1.68-52.26, P = .01). A higher vasoactive inotrope score (VIS) on postoperative day (POD) 0 was associated with fluid corrected AKI (odds ratio: 1.20, 95% CI: 1.06-1.35; P = .003). Conclusions: Acute kidney injury is common after the Norwood procedure. Correcting creatinine for fluid balance revealed new cases of AKI. Use of an mBTS and higher VIS on POD 0 were associated with increased risk of AKI.

Patterns of Care in Patients with Chemotherapy Receiving Erythropoiesis Stimulating Agents (ESAs).

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 964-964 ◽  
Author(s):  
Arash Naeim ◽  
Lyssa Friedman ◽  
Eric Elkin ◽  
Sara Adams ◽  
Hema Viswanathan ◽  
...  
Keyword(s):  
Risk Factors ◽  
Treatment Initiation ◽  
Retrospective Chart Review ◽  
Patterns Of Care ◽  
Chronic Obstructive ◽  
Policy Debate ◽  
National Guidelines ◽  
Obstructive Pulmonary Disease ◽  
Recommended Treatment ◽  
The Impact

Abstract Background: Hemoglobin (Hb) levels at ESA treatment initiation have undergone recent policy debate. This retrospective chart review used baseline data prior to an educational intervention on anemia guidelines in community-based oncology practices to understand ESA patterns of care among cancer patients receiving chemotherapy. National guidelines at the time of data collection recommended treatment when Hb was <11 g/dL or when Hb was 11–12 g/dL in the presence of anemia symptoms or risk factors for development of symptomatic anemia. The objectives of this analysis were to examine Hb levels and presence of symptoms or risk factors at ESA treatment initiation and proportion of patients receiving at least one transfusion after initial ESA treatment. Methods: Medical charts of patients ≥18 years receiving chemotherapy (June 2005 – August 2006) for lung, ovarian, multiple myeloma, Hodgkin’s and non-Hodgkin’s lymphoma, colorectal, breast, head and neck, bladder or testicular cancer from 47 sites were abstracted. Hb level at initial ESA administration was defined as the value recorded within 7 days prior to or on the day of treatment initiation. Anemia symptoms (chest pain, peripheral edema, sustained tachycardia, severe fatigue, dizziness) and risk factors for the development of symptomatic anemia (prior transfusion, radiation or chemotherapy; chronic obstructive pulmonary disease, cerebrovascular disease or cardiac disease; age ≥ 65 years) were identified using national guidelines. Results: Of 2844 patients on chemotherapy, mean age was 62 years; 66% were female; most common malignancies were breast (36%), non-small cell lung cancer (19%) and colorectal (18%). A total of 1268 patients (44%) received at least one administration of an ESA and of these 1165 (92%) had Hb levels recorded at treatment initiation. A total of 238 patients (20%) had Hb levels ≤10g/dL at ESA initiation, 419 (36%) had Hb levels from 10.1–11.0 g/dL, 358 (31%) had Hb levels from 11.1–12.0 g/dL and 150 (13%) had Hb levels >12g/dL at treatment initiation. Of the 1268 patients who received initial treatment with an ESA, 102 (8%) required at least one transfusion during chemotherapy. Anemia symptoms or risk factors were present in 206 patients (87%) with Hb ≤10g/dL, 335 (80%) with Hb 10.1–11.0 g/dL and 287 (80%) with Hb 11.1–12.0 g/dL at ESA treatment initiation. Of the 1616 patients (56%) who did not receive an ESA during chemotherapy, the majority had a lowest recorded Hb level >12g/dL (647 patients, 40%) and 68% of such patients had anemia symptoms or risk factors. In comparison, 83% of patients receiving an initial ESA administration at Hb >12 g/dL had anemia symptoms or risk factors. Conclusions: Initiation of ESAs occurred most commonly between Hb levels of 10.1–11.0 g/dL. A majority of patients had symptoms or risk factors at ESA treatment initiation across Hb levels. Evaluation of specific symptoms and the role of ESAs in symptom alleviation is needed. Future studies should investigate the impact of new polices for ESA use on utilization patterns. Hb Levels at ESA Treatment Initiation and Presence of Symptoms or Risk Factors (N=1165)* ESA Treatment Presence of Symptoms or Risk Factors Hb at ESA Treatment Initiation N % N % *n=102 with no Hb in week prior to initial ESA treatment ≤10 238 20.4 206 86.6 >10–11 419 36.0 335 80.0 >11–12 358 30.7 287 80.2 >12 150 12.9 125 83.3

Sign in / Sign up

Export Citation Format

Share Document